Cipher Pharmaceuticals Inc. (DND.TO)


Toronto - Toronto Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close0.00
Open0.00
Volume0
Day's Range0.00 - 0.00
52wk Range
Avg Vol (3m)N/A
  • Zacks Small Cap Research11 months ago

    CPHR: Total Revenue Grew 28% in Third Quarter of 2015

    Revenue growth in third quarter of 2015 was mainly driven by strong growth in product sales, which was up 367% compared to that for third quarter of 2014. Product revenue growth was primarily a result of the acquisition of Innocutis completed in April 2015, which added 7 commercial products marketed in the US. Canadian product revenue from Epuris and Vaniqa sales in 3Q15 increased by 63% compared to 3Q14, with Vaniqa contributing 20% of that growth amount.

  • Zacks Small Cap Researchlast year

    CPHR: Product Sales Picked Up Steam in Second Quarter of 2015

    Total revenue for the second quarter of 2015 was $8.8 million, compared to $8.0 million for the second quarter of 2014, an increase of 10%. Revenue growth in second quarter of 2015 was mainly driven by strong growth in product sales, which was up 451% compared to that for second quarter of 2014. The high growth in product sales was offset by decline in licensing revenue in the second quarter of 2015, which was down 16%.

  • Associated Presslast year

    Cipher Pharmaceuticals posts 1Q profit

    The Mississauga, Ontario-based company said it had net income of 9 cents per share. The drugmaker posted revenue of $7.3 million (9.2 million CAD) in the period. Cipher Pharmaceuticals shares have fallen ...